3',4'-dichloro-2-methylpropananilide | 882-14-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3',4'-dichloro-2-methylpropananilide
• 英文别名: N-(3,4-dichlorophenyl)-isobutyramide；DNI；3',4'-dichloroisobutyranilide；Isopropyl-N-3,4-dichlorphenylcarbamat；3,4-Dichlor-N-isobutyryl-anilin；3',4'-Dichlor-isobutyranilid；N-(3,4-dichlorophenyl)-2-methylpropanamide
• CAS: 882-14-4
• 化学式: C₁₀H₁₁Cl₂NO
• mdl: MFCD01183457
• 分子量: 232.109
• InChiKey: VVFDYYARGWIPOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3,4-二氯硝基苯 、 异丁酸 在 sodium sulfite 作用下， 反应 16.0h， 以85%的产率得到3',4'-dichloro-2-methylpropananilide
  参考文献：
  名称：

  亚硫酸钠在羧酸中还原酰化硝基芳烃为苯胺

  摘要：

  首次报道了使用亚硫酸钠-羧酸体系将芳香族硝基化合物轻松有效地还原酰化为相应的苯胺。硫化钠...

  DOI：

  10.1246/cl.140454

文献信息

• [EN] POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AND COMBINATION THERAPY<br/>[FR] POTENTIALISATEURS D'ANTIBIOTIQUES DE TYPE BÊTA-LACTAMES ET POLYTHÉRAPIE
  申请人：UNIV NOTRE DAME DU LAC

  公开号：WO2017106552A1

  公开（公告）日：2017-06-22

  Proteins of methicillin-resistant Staphylococcus aureus (MRSA), an antibiotic sensor/signal transducer, are phosphorylated on exposure to β-lactam antibiotics. This event is critical for the onset of the biochemical events that unleash induction of antibiotic resistance. The phosphorylation and the antibiotic-resistance phenotype can be abrogated in the presence of inhibitors described herein that restore susceptibility of the organism to β- lactam antibiotics. The invention thus provides compounds and methods for abrogating antibiotic resistance to β-lactam antibiotics and for treating infections causes by antibiotics prone to developing resistance by potentiating β-lactam antibiotics.

  耐甲氧西林金黄色葡萄球菌（MRSA）的蛋白质是一种抗生素感应器/信号传导体，在暴露于β-内酰胺类抗生素时会发生磷酸化。这一事件对于引发生物化学事件的开始至关重要，从而诱导抗生素抗性。在本文所述的抑制剂存在的情况下，磷酸化和抗生素抗性表型可以被废除，从而恢复该生物对β-内酰胺类抗生素的敏感性。因此，该发明提供了化合物和方法，用于废除对β-内酰胺类抗生素的抗性，并通过增强β-内酰胺类抗生素来治疗由易于产生抗性的抗生素引起的感染。
• Substituted pyrazoles as p38 kinase inhibitors
  申请人：Naraian S. Ashok

  公开号：US20070078146A1

  公开（公告）日：2007-04-05

  A class of pyrazole derivatives is described for use in treating p38 kinase medicated disorders. Compounds of particular interest are defined by Formula IA wherein R 1 , R 2 , R 3 and R 4 are as described in the specification.

  描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。特别感兴趣的化合物由公式IA定义，其中R1、R2、R3和R4如规范中所述。
• Method for inhibiting osteoclast development
  申请人：West Virginia University

  公开号：US10682320B2

  公开（公告）日：2020-06-16

  This invention provides a composition comprising Formula I, or salt thereof, wherein X is either chlorine or bromine, Y is either hydrogen or an alkyl group having a carbon chain length from 1 to 5 carbon atoms, and R is an alkyl group having a carbon chain length from 1 to 5 carbon atoms, except that X is not chlorine when Y is hydrogen and R is an ethyl group. A method of preventing bone erosion in a patient and a method of reducing inflammation in a patient using the compositions of Formula I are disclosed.

  本发明提供了一种由式 I 或其盐组成的组合物、 其中X为氯或溴，Y为氢或碳链长度为1至5个碳原子的烷基，R为碳链长度为1至5个碳原子的烷基，但当Y为氢和R为乙基时，X不是氯。本发明公开了一种使用式 I 组合物防止患者骨质侵蚀的方法和一种减轻患者炎症的方法。
• Method For Inhibiting Osteoclast Development
  申请人：Barnett John B.

  公开号：US20130303621A1

  公开（公告）日：2013-11-14

  This invention provides a composition comprising Formula I, or salt thereof, wherein X is either chlorine or bromine, Y is either hydrogen or an alkyl group having a carbon chain length from 1 to 5 carbon atoms, and R is an alkyl group having a carbon chain length from 1 to 5 carbon atoms, except that X is not chlorine when Y is hydrogen and R is an ethyl group. A method of preventing bone erosion in a patient and a method of reducing inflammation in a patient using the compositions of Formula I are disclosed.
• Substituted Urea eIF2alpha Kinase Activators
  申请人：THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

  公开号：US20160318856A1

  公开（公告）日：2016-11-03

  This disclosure relates to substituted urea eIF2α kinase activators including methods of making and using the same. For example, such activators can include cycloalkyl aryl ureas, which activate at least one eIF2α kinase. These compounds may be useful for treatment of diseases such as, for example, cancer, hemolytic anemia not caused by infectious agents, Wolcott-Rallison syndrome, neurodegenerative disease, tuberous sclerosis complex, fragile-X syndrome, autism spectrum disorder, and ribosomal defect disease.